Seyed Isaac Hashemy

Seyed Isaac Hashemy

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Cristina CarvalhoCristina Carvalho
Cristina Carvalho
ECEng-Hui Chew
Eng-Hui Chew
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
Jun LuJun Lu
Jun Lu
AHArne Holmgren
Arne Holmgren
Mercury toxicity mediated by different forms of mercury is a major health problem; however, the molecular mechanisms underlying toxicity remain elusive. We analyzed the effects of mercuric chloride (HgCl2) and monomethylmercury (MeHg) on the proteins of the mammalian thioredoxin system, thioredoxin reductase (TrxR) and thioredoxin (Trx), and of the glutaredoxin system, glutathione reductase (GR) and glutaredoxin (Grx). HgCl2 and MeHg inhibited recombinant rat TrxR with IC50 values of 7.2 and 19.7 nm, respectively. Fully reduced human Trx1 bound mercury and lost all five free thiols and activity after incubation with HgCl2 or MeHg, but only HgCl2 generated dimers. Mass spectra analysis demonstrated binding of 2.5 mol of Hg2+ and 5 mol of MeHg+/mol of Trx1 with the very strong Hg2+ complexes involving active site and structural disulfides. Inhibition of both TrxR and Trx activity was observed in HeLa and HEK 293 cells treated with HgCl2 or MeHg. GR was inhibited by HgCl2 and MeHg in vitro, but no decrease in GR activity was detected in cell extracts treated with mercurials. Human Grx1 showed similar reactivity as Trx1 with both mercurial compounds, with the loss of all free thiols and Grx dimerization in the presence of HgCl2, but no inhibition of Grx activity was observed in lysates of HeLa cells exposed to mercury. Overall, mercury inhibition was selective toward the thioredoxin system. In particular, the remarkable potency of the mercury compounds to bind to the selenol-thiol in the active site of TrxR should be a major molecular mechanism of mercury toxicity.

1 February 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
NYNeda Yaghoubi
Neda Yaghoubi
ASArash Soltani
Arash Soltani
KGKiarash Ghazvini
Kiarash Ghazvini
SHSeyed Mahdi Hassanian
Seyed Mahdi Hassanian
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically been notable worldwide and many attempts have been made to raise the overall survival of CRC patients. Immune response has long been a question of great interest in a wide range of fields such as cancer therapies and anti-tumor immunity through checkpoint inhibitors, specifically anti PD-1/ PD-L1 interaction, is a new line of research for treatment of CRC patients. Following the successful development of anti-PD-1 for melanoma, renal cell carcinoma, and non-small cell lung cancer, several clinical trials have been conducted on monoclonal antibodies (MAbs) against PD-1 in CRC. There is a growing body of literature that recognizes the importance of anti-PD-1 therapy for MSI (Microsatellite instability) tumors among CRC subtypes. We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients.

1 August 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
AHArne Holmgren
Arne Holmgren
The mammalian cytosolic/nuclear thioredoxin system, comprising thioredoxin (Trx), selenoenzyme thioredoxin reductase (TrxR), and NADPH, is the major protein-disulfide reductase of the cell and has numerous functions. The active site of reduced Trx comprises Cys(32)-Gly-Pro-Cys(35) thiols that catalyze target disulfide reduction, generating a disulfide. Human Trx1 has also three structural Cys residues in positions 62, 69, and 73 that upon diamide oxidation induce a second Cys(62)-Cys(69) disulfide as well as dimers and multimers. We have discovered that after incubation with H(2)O(2) only monomeric two-disulfide molecules are generated, and they are inactive but able to regain full activity in an autocatalytic process in the presence of NADPH and TrxR. There are conflicting results regarding the effects of S-nitrosylation on Trx antioxidant functions and which residues are involved. We found that S-nitrosoglutathione-mediated S-nitrosylation at physiological pH is critically dependent on the redox state of Trx. Starting from fully reduced human Trx, both Cys(69) and Cys(73) were nitrosylated, and the active site formed a disulfide; the nitrosylated Trx was not a substrate for TrxR but regained activity after a lag phase consistent with autoactivation. Treatment of a two-disulfide form of Trx1 with S-nitrosoglutathione resulted in nitrosylation of Cys(73), which can act as a trans-nitrosylating agent as observed by others to control caspase 3 activity (Mitchell, D. A., and Marletta, M. A. (2005) Nat. Chem. Biol. 1, 154-158). The reversible inhibition of human Trx1 activity by H(2)O(2) and NO donors is suggested to act in cell signaling via temporal control of reduction for the transmission of oxidative and/or nitrosative signals in thiol redox control.

6 October 2018 in Journal of Herbmed Pharmacology
Verified
Journal Article
Open access
NBNadia Boroumand
Nadia Boroumand
SSSaeed Samarghandian
Saeed Samarghandian
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
Turmeric is a widely used spice derived from the rhizomes of Curcuma longa. Having been used as a dietary spice, it has drawn scientists’ attention to the possible medicinal benefits of its active compounds called curcuminoids which consist of curcumin, demethoxycurcumin and bisdemethoxycurcmin. Considering wide range of pharmacological properties that curcumin offers, numerous studies have investigated its potency as a therapeutic agent in various diseases such as autoimmune, cardiovascular, neoplastic, pulmonary, neurodegenerative and metabolic diseases. With regard to its wide array of health benefits and published data on the underlying mechanisms of its action, a complex interaction between three main events including inflammation, oxidative stress, and immunity, seems to contribute to different therapeutic roles of this compound. Hence, this review discusses the current knowledge on the anti-inflammatory, antioxidant, and immunomodulatory roles of curcumin with the hope of recruiting curcumin as a therapeutic agent in future therapeutic regimen in order to enhance the efficacy of the treatment, as well as decreasing the adverse effects of synthetic chemical drugs.

1 April 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
JUJohanna S. Ungerstedt
Johanna S. Ungerstedt
FAFarnaz Zahedi Avval
Farnaz Zahedi Avval
AHArne Holmgren
Arne Holmgren
Motexafin gadolinium (MGd) is a chemotherapeutic drug that selectively targets tumor cells and mediates redox reactions generating reactive oxygen species. Thioredoxin (Trx), NADPH, and thioredoxin reductase (TrxR) of the cytosol/nucleus or mitochondria are major thiol-dependent reductases with many functions in cell growth, defense against oxidative stress, and apoptosis. Mammalian TrxRs are selenocysteine-containing flavoenzymes; MGd was an NADPH-oxidizing substrate for human or rat TrxR1 with a Km value of 8.65 μm (kcat/Km of 4.86 × 104 m–1 s–1). The reaction involved redox cycling of MGd by oxygen producing superoxide and hydrogen peroxide. MGd acted as a non-competitive inhibitor (IC50 of 6 μm) for rat TrxR. In contrast, direct reaction between MGd and reduced human Trx was negligible. The corresponding reaction with reduced Escherichia coli Trx was also negligible, but MGd was a better substrate (kcat/Km of 2.23 × 105 m–1 s–1) for TrxR from E. coli and a strong inhibitor of Trx-dependent protein disulfide reduction. Ribonucleotide reductase (RNR), a 1:1 complex of the non-identical R1- and R2-subunits, catalyzes the essential de novo synthesis of deoxyribonucleotides for DNA synthesis using electrons from Trx and TrxR. MGd inhibited recombinant mouse RNR activity with either 3 μm reduced human Trx (IC50 2 μm) or 4 mm dithiothreitol (IC50 6 μm) as electron donors. Our results demonstrate MGd-induced enzymatic generation of reactive oxygen species by TrxR plus a powerful inhibition of RNR. This may explain the effects of the drug on cancer cells, which often overproduce TrxR and have induced RNR for replication and repair.

31 July 2019 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
FMFariba Mohammadi
Fariba Mohammadi
ASArash Soltani
Arash Soltani
AGAtefeh Ghahremanloo
Atefeh Ghahremanloo
HJHossein Javid
Hossein Javid
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy